# Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT

Study · id `cardio:ct-nct07720232` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07720232](<https://clinicaltrials.gov/study/NCT07720232>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07720232

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07720232. Randomized; double masking; primary purpose treatment. Start 2026-01-18 (actual); primary completion 2028-01-18 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07720232, source copy `cardio:ctgov-nct07720232-2026-07-22`, retrieved 2026-10-31)
- Started: 2026-01-18 (actual) (ClinicalTrials.gov record NCT07720232, source copy `cardio:ctgov-nct07720232-2026-07-22`, retrieved 2026-10-31)
- Primary completion: 2028-01-18 (anticipated) (ClinicalTrials.gov record NCT07720232, source copy `cardio:ctgov-nct07720232-2026-07-22`, retrieved 2026-10-31)
- Completion: 2029-02-18 (anticipated) (ClinicalTrials.gov record NCT07720232, source copy `cardio:ctgov-nct07720232-2026-07-22`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07720232, source copy `cardio:ctgov-nct07720232-2026-07-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07720232-2026-07-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
- Condition: Hypertriglyceridemic Acute Pancreatitis
- Condition: Acute Pancreatitis, Hypertriglyceridemia-induced
- Condition: Hyperlipidemia
- Intervention (Drug): Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE)
- Intervention (Drug): Standard Care (in control arm)
- Lead sponsor: Jianyin Zhou
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: fbf090ba90457399e6dea6d6519ac09ca8e48f3bcf30dc05223740d4eb12b7f7
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
